Free shipping on all orders over $ 500

Vipivotide tetraxetan

Cat. No. M9750
Vipivotide tetraxetan Structure
Synonym:

PSMA-617

Size Price Availability Quantity
1mg USD 200  USD200 In stock
5mg USD 700  USD700 In stock
10mg USD 1100  USD1100 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Vipivotide tetraxetan (PSMA-617) is a potent prostate-specific membrane antigen (PSMA) inhibitor with Ki value of 0.37 nM, it is used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA-617 has a high inhibition potency (equilibrium dissociation constant Ki=2.34±2.94 nM on LNCaP; Ki=0.37±0.21 nM enzymatically determined) and highly efficient internalization into LNCaP cells are demonstrated.

Chemical Information
Molecular Weight 1042.14
Formula C49H71N9O16
CAS Number 1702967-37-0
Solubility (25°C) DMSO ≥ 100 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Hendrik Rathke, et al. J Nucl Med. Response Prediction of 177 Lu-PSMA-617 Radioligand Therapy Using Prostate-Specific Antigen, Chromogranin A, and Lactate Dehydrogenase

[2] Sonam Suman, et al. Br J Radiol. Therapeutic efficacy, prognostic variables and clinical outcome of 177 Lu-PSMA-617 PRLT in progressive mCRPC following multiple lines of treatment: prognostic implications of high FDG uptake on dual tracer PET-CT vis-a-vis Gleason score in such cohort

[3] Martina Benesova, et al. J Nucl Med. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer

Related PSMA Products
Glu-urea-Glu-NHS ester

Glu-urea-Glu-NHS ester is an active NHS Glu-urea-Glu that acts as a pharmacophore for binding to prostate-specific membrane antigen (PSMA) inhibitors.

PSMA-1007

PSMA-1007 is a prostate-specific membrane antigen (PSMA) ligand.

PSMA targeting peptide

PSMA-1 is a PSMA targeting peptide (GRFLTGGTGRLLRIS) and can be used for for targeted delivery of glucose-regulated protein (GRP)-silencing siRNAs in PCa cells.

Pelgifatamab

Pelgifatamab is a monoclonal antibody targeting prostate cancer-specific membrane antigen (PSMA) for prostate cancer-related studies.

ARX-517

ARX-517 is an antibody-coupled compound (ADC) targeting prostate-specific membrane antigen (PSMA), which can be used in prostate cancer-related studies.

  Catalog
Abmole Inhibitor Catalog




Keywords: Vipivotide tetraxetan, PSMA-617 supplier, PSMA, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.